• EMA’s CHMP backed a broader EU label for Amgen’s Repatha to cut cardiovascular risk in adults with established or high-risk atherosclerotic disease.
• Opinion supports use before a first heart attack or stroke, based on the Phase 3 VESALIUS-CV trial in more than 12,000 patients.
• European Commission decision expected in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN14455) on July 29, 2026, and is solely responsible for the information contained therein.